| Literature DB >> 32754756 |
Whanhee Lee1, Seung-Sik Hwang1, Insung Song1, Chaerin Park1, Honghyok Kim2, In-Kyung Song3, Hayon Michelle Choi2, Kristi Prifti1, Younggyu Kwon1, Jeongheon Kim1, Seuk Oh1, Juyeon Yang1, Mirae Cha1, Yoonhee Kim4, Michelle L Bell2, Ho Kim1.
Abstract
BACKGROUND: South Korea experienced the novel coronavirus disease (COVID-19) outbreak in the early period; thus data from this country could provide significant implications for global mitigation strategies. This study reports how COVID-19 has spread in South Korea and examines the effects of rapid widespread diagnostic testing on the spread of the disease in the early epidemic phase.Entities:
Keywords: COVID-19 epidemic; South Korea; aggressive testing; epidemiological pattern; severe-patients-targeted treatment
Mesh:
Year: 2020 PMID: 32754756 PMCID: PMC7454567 DOI: 10.1093/ije/dyaa119
Source DB: PubMed Journal: Int J Epidemiol ISSN: 0300-5771 Impact factor: 7.196
COVID-19 case definition and diagnostic testing information in Korea. KCDC: Korea Centers for Disease Control and Prevention. All contents are reported in the Korea Centers for Disease Control and Prevention (KCDC) website [http://ncov.mohw.go.kr/]
| Description | |
|---|---|
| Case definition |
Confirmed cases: people who diagnostically test positive for the virus, regardless of clinical manifestations Death cases: deceased patients diagnosed with COVID-19. If the test result post-mortem was positive, then the patient was defined as a COVID-19 death All cases were registered in the KCDC Health and Disease Integrated Management System |
| Diagnostic test |
Testing: diagnostic testing is a viral test that detects current infection using RT-PCR (real-time reverse transcriptase-polymerase chain reaction) Specimen: upper respiratory tract specimen (nasopharyngeal and oropharyngeal swab tests) are collected by medical staff (doctors, nurses or clinical laboratory scientists) at designated locations (screening centres/stations). Lower respiratory tract specimens are also collected if the patient has sputum |
| Testing eligibility criteria |
Before 20 February 2020 Diagnostic testing was conducted only on suspected cases with epidemiological linkages to a confirmed case after physician instruction. Suspected cases were defined as persons exhibiting fever (37.5°C or higher) or respiratory symptoms within 14 days of contact with a confirmed COVID-19 patient during the latter’s symptom-exhibiting period Since 20 February 2020 (6th edition of COVID-19 guideline) The KCDC revised its testing eligibility criteria and effective 20 February (6th edition of COVID-19 guideline from the KCDC): both asymptomatic and symptomatic patients under investigation could get the diagnostic tests. Suspected cases were defined as: |
|
persons suspected of COVID-19 according to a physician’s opinion for reasons such as pneumonia of an unknown cause; or persons with overseas travel history exhibiting fever or respiratory symptoms during 14 days after entry; or persons exhibiting fever (37.5 °C or higher) or respiratory symptoms (coughs, shortness of breath etc.) within 14 days from an epidemiological link to a domestic COVID-19 cluster |
Figure 1Daily series of COVID-19 cases with major interventions in Korea. The period shown ranges from 20 January (date of the first confirmed case in Korea) to 13 April 2020 (last day of the study). The major interventions indicate those implemented by the Korea Centers for Disease Control and Prevention (KCDC) and the Korean government
Figure 2Epidemiological aspects of COVID-19 in Korea after the beginning of the epidemic in Daegu (18 February 2020). (A) Daily series of cumulative confirmed COVID-19 cases. (B) Daily series of confirmed cases after 18 February 2020 (yellow) with imported cases counted from 25 March. (C) Geographical distribution of confirmed cases across all metropolitan/special cities and provinces in Korea. Metropolitan/special cities and provinces were divided into three areas: Daegu (the epicentre), neighbouring (regions adjacent to Daegu) and other areas. Coloured dots indicate the cumulative number of confirmed cases on 13 April. (D) Estimated logistic growth curve for the cumulative COVID-19 cases in Korea with peak (red) and plateau (blue) points. (E) Time-varying reproduction number (Rt) of COVID-19 in Korea with 95% credible intervals. The vertical lines indicate peak (red) and plateau (blue) points. (F) Time-varying epidemic doubling time; 7-day rolling estimates were applied. The vertical lines indicate peak (red) and plateau (blue) points.
Epidemiological aspects of the COVID-19 in Korea. Time: the number of days from the beginning of the COVID-19 outbreak in Korea (18 February 2020: the first diagnosed case in Daegu) to each time point. Daily cases: the modelled daily confirmed cases at each time point. Rt: estimated reproduction numbers at each time point, t. Doubling time: epidemic doubling time from 18 February 2020 to each time point. Neighbouring: neighboring areas around Daegu
| Time points (t) | Time from initial outbreak (days) | Daily cases | Rt | Doubling time (days) | |
|---|---|---|---|---|---|
| National | After a week | – | 244.9 (226.7 to 263.3) | 3.9 (3.7 to 4.2) | 3.8 (3.4 to 4.2) |
| Peak | 15.2 (15 to 16) | 537.8 (495.9 to 583.6) | 2.2 (2.1 to 2.2) | 4.8 (4.3 to 5.3) | |
| Plateau | 25.8 (25 to 26) | 167.0 (152.5 to 184.0) | 0.5 (0.4 to 0.5) | 17.4 (16.2 to 18.9) | |
| Areas | |||||
| Daegu | After a week | – | 174.1 (161.4 to 185.5) | 4.2 (3.8 to 4.5) | 2.9 (2.6 to 3.1) |
| Peak | 14.3 (14 to 15) | 483.1 (455.2 to 512.7) | 2.7 (2.6 to 2.8) | 3.4 (3.1 to 3.7) | |
| Plateau | 23.4 (23 to 24) | 120.3 (103.9 to 133.6) | 0.6 (0.6 to 0.7) | 11.3 (10.7 to 11.9) | |
| Neighbouring | After a week | – | 52.8 (50.3 to 55.4) | 3.5 (3.2 to 4.0) | 3.6 (3.3 to 3.9) |
| Peak | 13.5 (13 to 14) | 93.1 (87.4 to 99.3) | 1.7 (1.5 to 1.8) | 4.6 (4.2 to 5.0) | |
| Plateau | 23.7 (23 to 24) | 26.6 (24.2 to 29.7) | 0.6 (0.5 to 0.6) | 16.9 (15.9 to 18.0) | |
| Others | After a week | – | 14.0 (13.4 to 14.5) | 3.8 (3.0 to 4.7) | 9.2 (8.7 to 9.8) |
| Peak | 32.3 (31 to 33) | 44.7 (43.3 to 46.2) | 0.9 (0.8 to 1.0) | 14.1 (13.5 to 14.7) | |
| Plateau | 46.3 (45 to 48) | 29.9 (28.8 to 30.8) | 0.5 (0.4 to 0.6) | 29.0 (27.5 to 30.8) | |
| Age groups | |||||
| 0–19 y | After a week | – | 11.5 (10.3 to 12.7) | 6.8 (4.5 to 9.7) | 4.2 (3.7 to 4.7) |
| Peak | 17.9 (17 to 18) | 32.6 (29.9 to 35.7) | 1.6 (1.4 to 1.8) | 5.6 (4.9 to 6.4) | |
| Plateau | 28.8 (28 to 30) | 11.3 (10.4 to 12.3) | 0.4 (0.3 to 0.5) | 19.1 (17.5 to 21.0) | |
| 20–39 y | After a week | – | 101.7 (91.0 to 111.4) | 4.6 (4.1 to 5.2) | 3.4 (3.0 to 3.9) |
| Peak | 14.7 (14 to 15) | 227.1 (203.7 to 254.0) | 2.2 (2.1 to 2.3) | 4.4 (3.8 to 5.1) | |
| Plateau | 24.5 (24 to 25) | 64.5 (57.7 to 71.2) | 0.4 (0.4 to 0.5) | 16.7 (15.0 to 18.6) | |
| 40–59 y | After a week | – | 85.5 (80.1 to 90.9) | 3.8 (3.4 to 4.2) | 4.0 (3.6 to 4.4) |
| Peak | 15.0 (15 to 15) | 171.5 (159.3 to 185.1) | 2.1 (1.9 to 2.2) | 5.1 (4.6 to 5.6) | |
| Plateau | 25.7 (25 to 26) | 54.6 (50.1 to 60.0) | 0.5 (0.5 to 0.6) | 18.3 (16.9 to 19.9) | |
| 60–79 y | After a week | – | 41.6 (39.0 to 44.2) | 3.1 (2.6 to 3.6) | 4.7 (4.2 to 5.1) |
| Peak | 16.9 (16 to 17) | 89.3 (83.1 to 96.7) | 1.6 (1.5 to 1.7) | 6.2 (5.6 to 6.9) | |
| Plateau | 28.3 (28 to 29) | 33.3 (30.9 to 35.8) | 0.4 (0.4 to 0.5) | 18.9 (17.6 to 20.3) | |
| 80+ y | After a week | – | 4.9 (4.5 to 5.3) | 4.0 (1.8 to 7.0) | 5.8 (5.3 to 6.3) |
| Peak | 24.0 (23 to 25) | 17.5 (16.5 to 18.7) | 1.0 (0.8 to 1.2) | 8.4 (7.8 to 9.1) | |
| Plateau | 36.4 (36 to 37) | 8.4 (7.9 to 8.9) | 1.4 (1.2 to 1.6) | 21.9 (20.6 to 23.5) | |
| Sex | |||||
| Male | After a week | – | 87.8 (80.9 to 94.5) | 3.4 (3.1 to 3.8) | 4.8 (4.3 to 5.4) |
| Peak | 16.8 (16 to 17) | 177.7 (162.9 to 196.9) | 1.6 (1.5 to 1.7) | 6.5 (5.7 to 7.3) | |
| Plateau | 28.4 (27 to 29) | 68.1 (63.2 to 73.1) | 0.4 (0.4 to 0.5) | 19.2 (17.6 to 21.0) | |
| Female | After a week | – | 153.2 (141.3 to 164.1) | 4.3 (3.9 to 4.7) | 3.8 (3.4 to 4.2) |
| Peak | 15.1 (15 to 16) | 337.9 (310.5 to 366.7) | 2.1 (2.1 to 2.2) | 4.7 (4.2 to 5.3) | |
| Plateau | 25.6 (25 to 26) | 103.2 (94.0 to 113.7) | 0.4 (0.4 to 0.4) | 17.9 (16.5 to 19.4) |
Figure 3Logistic growth curve and time-varying reproduction number (Rt) of COVID-19 by area, age-group and sex in Korea. (A) and( B) by area for Daegu, neighbouring area and other areas; (C) and (D) are by age groups; and (E) and (F) by sex. Panels A, C and E show logistic growth curves; B, D and F show time-varying Rt. The dots on the curves indicate the estimates at peak (red) and plateau (blue) points.
Figure 4Effects of testing on reduction in COVID-19 spread: during 4 weeks from the beginning of epidemic (18 February 2020) in Korea. (A) Changes in the number of daily confirmed cases (i.e. the speed of transmission; green), and the number of tests (pink). (B) Changes in newly confirmed cases per 1000 tests for 14 lag-days. (C) Seven-day moving average number of tests (pink) and time-varying reproduction number (Rt; purple). (D) Seven-day rolling associations between the 7-day moving average number of tests and time-varying Rt.
Figure 5Fatality aspects of COVID-19 in Korea. (A) Daily death counts of COVID-19. (B) Daily percentage of new deaths compared with the number of cumulative confirmed cases. Dashed lines in Panels A and B indicate the date of the announcement of the seventh revised guidance for the COVID-19 response system. (C) Case fatality rates on 13 April 2020 for each region in Korea. The study region was divided into three areas: Daegu (the epicentre), neighbouring (areas neighbouring Daegu) and other areas. Regions are arranged in order of case fatality rate.
Associations between medical indicators and fatality rate with the total cases at region level. Associations are expressed as changes in case fatality rate (CFR) with 95% confidence interval per unit increase in each indicator. Regional population, sex ratio, the percentage of people aged ≥ 60 years, gross regional domestic product (GRDP) per capita and age-sex standardized smoking prevalence were considered as confounders
| Indicator | Reduction in CFR(95% CI) |
|
|---|---|---|
| Number of beds in the hospital (per 1000 beds) | 0.51 (-0.03 to 1.04) | 0.106 |
| Number of beds in intensive care unit (ICU; per bed) | 0.01 (0.00 to 0.02) | 0.065 |
| Number of negative pressure beds (per bed) | 0.25 (0.06 to 0.45) | 0.038 |
| Number of hospitals equipped with the ECMO | 0.47 (-0.03 to 0.98) | 0.107 |
| Number of ECMO (per machine) | 0.13 (0.03 to 0.23) | 0.042 |
ECMO machine: extracorporeal membrane oxygenation machine.